145 related articles for article (PubMed ID: 23025988)
1. Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
Chen X; Chang CH; Stein R; Cardillo TM; Gold DV; Goldenberg DM
Biol Blood Marrow Transplant; 2013 Jan; 19(1):28-39. PubMed ID: 23025988
[TBL] [Abstract][Full Text] [Related]
2. CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.
Park HB; Oh K; Garmaa N; Seo MW; Byoun OJ; Lee HY; Lee DS
Transplantation; 2010 Oct; 90(8):825-35. PubMed ID: 20697326
[TBL] [Abstract][Full Text] [Related]
3. Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody.
Hatano R; Ohnuma K; Yamamoto J; Dang NH; Yamada T; Morimoto C
Br J Haematol; 2013 Jul; 162(2):263-77. PubMed ID: 23692598
[TBL] [Abstract][Full Text] [Related]
4. Migration and activation of T cells during development of graft-versus-host disease in a mouse model.
Wen HS; Wang JM; Zhou H; Gong SI; Gao L; Wu Y
Transplant Proc; 2013 Mar; 45(2):713-8. PubMed ID: 23498811
[TBL] [Abstract][Full Text] [Related]
5. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells.
Rus V; Svetic A; Nguyen P; Gause WC; Via CS
J Immunol; 1995 Sep; 155(5):2396-406. PubMed ID: 7650373
[TBL] [Abstract][Full Text] [Related]
7. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
9. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
[TBL] [Abstract][Full Text] [Related]
10. Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice.
Zheng J; Liu Y; Liu Y; Liu M; Xiang Z; Lam KT; Lewis DB; Lau YL; Tu W
Sci Transl Med; 2013 Jan; 5(168):168ra9. PubMed ID: 23325802
[TBL] [Abstract][Full Text] [Related]
11. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
[TBL] [Abstract][Full Text] [Related]
12. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions.
Mutis T; Aarts-Riemens T; Verdonck LF
Haematologica; 2005 Oct; 90(10):1389-95. PubMed ID: 16219576
[TBL] [Abstract][Full Text] [Related]
13. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.
Mutis T; van Rijn RS; Simonetti ER; Aarts-Riemens T; Emmelot ME; van Bloois L; Martens A; Verdonck LF; Ebeling SB
Clin Cancer Res; 2006 Sep; 12(18):5520-5. PubMed ID: 17000688
[TBL] [Abstract][Full Text] [Related]
14. Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells.
Kuwatani M; Ikarashi Y; Iizuka A; Kawakami C; Quinn G; Heike Y; Yoshida M; Asaka M; Takaue Y; Wakasugi H
Immunol Lett; 2006 Jul; 106(1):82-90. PubMed ID: 16806496
[TBL] [Abstract][Full Text] [Related]
15. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
Sykes M; Abraham VS; Harty MW; Pearson DA
J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
[TBL] [Abstract][Full Text] [Related]
16. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells.
Tang W; Yang Y; Zhang F; Li YC; Zhou R; Wang JX; Zhu YN; Li XY; Yang YF; Zuo JP
Int Immunopharmacol; 2005 Dec; 5(13-14):1904-13. PubMed ID: 16275625
[TBL] [Abstract][Full Text] [Related]
17. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
[TBL] [Abstract][Full Text] [Related]
18. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
19. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
20. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
